November 8th, 2024
Description
This program will address the management of refractory thyroid cancer, surveillance for low risk thyroid cancer, and evaluation of indeterminate thyroid nodules. Current practice patterns reflect a lack of understanding of the appropriate timing for interventions in patients with refractory thyroid cancer by using a targeted molecular therapy. Referrals are made requesting a clinical trial when a patient is not a candidate and serial monitoring is more appropriate. Additionally, those patients with low risk thyroid cancer continue to receive necessary treatment, including total (or completion thyroidectomy), radioiodine therapy, and suppressive doses of levothyroxine therapy. Finally, questions arise regarding the appropriate use of molecular markers in patients with indeterminate nodules. This conference will address these issues in an attempt to clarify the appropriate timing and use of systemic therapies, including redifferentiation therapy, as well as the indications for radioiodine therapy, completion thyroidectomy, and levothyroxine suppression therapy. Finally, we will discuss the currently available molecular markers with particular emphasis on their limitations and the indications for use of each type.
For pricing information, see pricing tab below.
Dates and Times
Start: 11/8/2024 8:00 AM
End: 11/8/2024 4:15 PM
Objectives
- Outline new recommendations regarding the management of low risk thyroid cancer
- Discuss the indications and complications of radiofrequency ablation of thyroid nodules and cancer
- Review the sonographic risk stratification of thyroid nodules
- Review the long term surveillance strategies for thyroid cancer
- Discuss emerging systemic therapies for progressive thyroid cancer
Agenda
Friday, November 8, 2024
7:15 am Registration and Continental breakfast
8:00 am OPENING REMARKS and INTRODUCTIONS
Matthew Ringel, MD/ Jennifer Sipos, MD
SESSION ONE: Defining Pathways of Thyroid Cancer: Development and Progression
SESSION CHAIR: Matthew Ringel
New Advances in Defining Signaling Pathways in Thyroid Cancer
Formation, Progression and Therapeutic Responses
8:10-8:45 am Matthew Ringel—Long telomere syndrome and thyroid cancer.
8:45-8:50 am Questions
8:50-9:40 am Ian Ganly--Mutational landscape of oncocytic neoplasms
9:40-9:45 am Questions
9:45-10:20am Priya Dedhia--Organelle models for medullary thyroid cancer pathogenesis and signaling
10:20-10:25am Questions
10:25-10.45 am Break
Genetics of Inherited Thyroid Cancer
10:45-11:20 am Pam Brock—When to recommend germline testing based in patients with thyroid cancer
11:20-11:25 am Questions
11:25-12:00 pm Jennifer Sipos—Molecular profiling: Individualizing treatment decisions and prognosis
12:00-12:05 pm Questions
LUNCH BREAK: Meet the professors (concurrent sessions)
1) Hamza Gokozan—Updates in thyroid cytology and pathology—the 2023 Bethesda system and 2022 WHO
2) John Phay—Intraoperative visualization of parathyroids
3) Dipen Patel—An update on clinical trials for iodine-refractory thyroid cancer
SESSION TWO: Thyroid Cancer Management
SESSION CHAIR: Jennifer Sipos
Current Concepts in the Management of Differentiated Thyroid Cancer
1:15-1:45pm Irina Azaryan—Controversies in early stage thyroid cancer
1:45-1:50 pm Questions
1:50-2:40 pm Maria Papaleontiou—De-escalation of care for low risk thyroid cancer
2:40-2:45 pm Questions
2:45 pm Afternoon Break (10 minutes)
Management of Advanced Thyroid Cancer
3:00-3:30 pm Bhavana Konda, MD Redifferentiation therapy—does it work?
3:30-3:35pm Questions
3:35-4:15 Tumor Board---aggressive cases of thyroid cancer: Fadi Nabhan moderator.
Panelists: Vineeth Sukrithan, Abby Lott-Limbach, Barbra Miller, Amit Agrawal
4:15pm Concluding remarks, Evaluations and Adjourn
Pricing
| Tier | Price |
|---|---|
| MD, PhD, APP, NP | $150.00 |
| Trainees, Students, Residents | $50.00 |
| Industry | $150.00 |
Speakers
Panels
Location
Biomedical Research Tower
460 W. 12th Ave.
Columbus, OH 43210
Accreditation Statement
The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The Ohio State University designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.